{"filing":{"accession_number":"0001104659-26-082902","cik":"0001710072","ticker":"EWTX","company_name":"Edgewise Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"tm2620181d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_8k.htm"},"events":[{"id":17514,"run_id":15688,"accession_number":"0001104659-26-082902","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Edgewise completed the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (total consideration up to $2.65 billion), completed on July 10, 2026. This material disposition fundamentally reshapes the company's strategic focus toward cardiovascular programs.","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16017,"accession_number":"0001104659-26-082902","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 2.01 discloses the completion of a material asset disposition: Edgewise sold its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (aggregate $2.65 billion). The filing explicitly states the transaction was \"completed on July 10, 2026\" and describes the asset transfer, consideration, and strategic implications. This is a classic M\u0026A activity—a material disposition of a significant business asset that fundamentally reshapes the company's focus to cardiovascular programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:38:40.359848+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16018,"accession_number":"0001104659-26-082902","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material asset sale transaction in which Servier acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (total consideration up to $2.65 billion). This represents a significant disposition of a business unit that materially affects the company's strategic focus and financial position, transforming it into a cardiovascular-focused company. The transaction is explicitly described as a \"definitive agreement\" that has been \"successfully completed,\" triggering Item 1.02 or 2.01 disclosure requirements for material dispositions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:38:40.359848+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16017,"accession_number":"0001104659-26-082902","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This Item 2.01 discloses the completion of a material asset disposition: Edgewise sold its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (aggregate $2.65 billion). The filing explicitly states the transaction was \"completed on July 10, 2026\" and describes the asset transfer, consideration, and strategic implications. This is a classic M\u0026A activity—a material disposition of a significant business asset that fundamentally reshapes the company's focus to cardiovascular programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:38:40.359848+00:00","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-07-13"},{"id":16018,"accession_number":"0001104659-26-082902","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material asset sale transaction in which Servier acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (total consideration up to $2.65 billion). This represents a significant disposition of a business unit that materially affects the company's strategic focus and financial position, transforming it into a cardiovascular-focused company. The transaction is explicitly described as a \"definitive agreement\" that has been \"successfully completed,\" triggering Item 1.02 or 2.01 disclosure requirements for material dispositions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:38:40.359848+00:00","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-07-13"}]}